09:40 às 10:50 - Sessão 1 - Best of SABCS 2022 - parte 2

09:40 às 09:50 - - GS1-09 Abemaciclib plus endocrine therapy for HR+, HER2-, node-positive, high-risk early breast cancer: results from a pre-planned monarchE overall survival interim analysis, including 4-year efficacy outcomes